Abstract
Rhesus macaques (M. mulatta), immunized with an inactivated whole SIVmac vaccine and muramyl dipeptide or Freund's incomplete adjuvant, were protected against IV challenge infection with 10 animal infectious doses of the homologous virus. The protection in these animals appeared to be complete, with no breakthrough of latent virus infection over a 10-month period. Vaccine protection in this model was correlated generally with a high level of SIVmac envelope antibody by ELISA and immunoblot, high titers of syncytial inhibiting antibody, and, more specifically, with the presence of antibodies binding to a putative V3 loop synthetic peptide of the SIVmac outer envelope. This model can now be used for further identification of the protective epitopes and protective host immune responses as well as for development of novel and better AIDS vaccines.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylmuramyl-Alanyl-Isoglutamine / administration & dosage
-
Animals
-
Antibodies, Viral / biosynthesis
-
Antigens, Viral
-
Freund's Adjuvant / administration & dosage
-
Gene Products, env / immunology
-
Macaca mulatta
-
Neutralization Tests
-
Retroviridae Proteins, Oncogenic / immunology
-
Simian Acquired Immunodeficiency Syndrome / prevention & control*
-
Simian Immunodeficiency Virus / immunology*
-
Vaccines, Inactivated / administration & dosage
-
Vaccines, Inactivated / pharmacology
-
Viral Fusion Proteins*
-
Viral Vaccines / administration & dosage
-
Viral Vaccines / pharmacology*
Substances
-
Antibodies, Viral
-
Antigens, Viral
-
Gene Products, env
-
Retroviridae Proteins, Oncogenic
-
Vaccines, Inactivated
-
Viral Fusion Proteins
-
Viral Vaccines
-
transmembrane protein, Simian immunodeficiency virus
-
Acetylmuramyl-Alanyl-Isoglutamine
-
Freund's Adjuvant